secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2023-07-03T23:59:59+00:00
Accession:  0001104659-23-077599
Event type: regulatory
Sentiment:  neutral
Materiality: 0.30
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Therapeutics receives Nasdaq non-compliance notice for audit committee vacancy
--------------------------------------------------------------------------------

- On June 27, 2023, Nasdaq confirmed Protagonist is not compliant with Listing Rule 5605 requiring an audit committee of at least three independent directors.
- The vacancy arose after Sarah Noonberg, M.D., Ph.D. did not stand for re-election at the May 25, 2023 annual meeting.
- Company has a cure period until the earlier of its next annual meeting or May 27, 2024 to fill the audit committee seat.
- Board is in the process of identifying and selecting a new independent director to meet Nasdaq requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465923077599/0001104659-23-077599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465923077599/tm2320477d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-077599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer